Timing, Fundamentals, and Diversification of PharmaCyte Biotech Inc. (PMCB)

The closing price of PharmaCyte Biotech Inc. (NASDAQ: PMCB) was $3.07 for the day, up 2.33% from the previous closing price of $3.00. In other words, the price has increased by $+0.0700 from its previous closing price. On the day, 106633 shares were traded. PMCB stock price reached its highest trading level at $3.0900 during the session, while it also had its lowest trading level at $2.9900.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.



Our analysis of PMCB’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 75.50 and its Current Ratio is at 75.50. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

Stock Price History:

Over the past 52 weeks, PMCB has reached a high of $3.10, while it has fallen to a 52-week low of $1.79. The 50-Day Moving Average of the stock is 2.7523, while the 200-Day Moving Average is calculated to be 2.4116.

Shares Statistics:

PMCB traded an average of 94.59K shares per day over the past three months and 58.75k shares per day over the past ten days. A total of 20.83M shares are outstanding, with a floating share count of 19.87M. Insiders hold about 0.20% of the company’s shares, while institutions hold 30.40% stake in the company. Shares short for PMCB as of Oct 13, 2022 were 77.85k with a Short Ratio of 0.09M, compared to 102.29k on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 0.38% and a Short% of Float of 0.38%.

Earnings Estimates

The firm’s stock currently is rated by 1 analysts. On average, analysts expect EPS of -$0.08 for the current quarter, with a high estimate of -$0.08 and a low estimate of -$0.08, while EPS last year was -$0.06. The consensus estimate for the next quarter is -$0.08, with high estimates of -$0.08 and low estimates of -$0.08.

Analysts are recommending an EPS of between -$0.32 and -$0.32 for the fiscal current year, implying an average EPS of -$0.32. EPS for the following year is -$0.38, with 1 analysts recommending between -$0.38 and -$0.38.